A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement

Journal of Parkinson's Disease

Volumn 7, Issue 3, 2017, Pages 533-543

  De Roos, Paul ^a,c   Bloem, Bastiaan R ^b   Kelley, Thomas A ^c   Antonini, Angelo ^d,e   Dodel, Richard ^f   Hagell, Peter ^g   Marras, Connie ^h   Martinez Martin, Pablo ⁱ   Mehta, Shyamal H ^j   Odin, Per ^k   Chaudhuri, Kallol Ray ^l   Weintraub, Daniel ^m,n   Wilson, Bil ^o   Uitti, Ryan J ^p  

^a UPPSALA UNIVERSITY   (Sweden)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c International Consortium for Health Outcomes Measurement   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e Fondazione Ospedale San Camillo IRCCS   (Italy)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g KRISTIANSTAD UNIVERSITY   (Sweden)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j MAYO CLINIC   (United States)

^k LUND UNIVERSITY HOSPITAL   (Sweden)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^o ICHOM Patient Representative   (United States)

^p MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CANADA; CONSENSUS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; GERMANY; HEALTH CARE; HEALTH CARE SYSTEM; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; ITALY; NATIONAL HEALTH SERVICE; NETHERLANDS; NEUROLOGY; NURSING; OUTCOME ASSESSMENT; PARKINSON DISEASE; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRY; SPAIN; SWEDEN; TELECONFERENCE; UNITED KINGDOM; UNITED STATES; FEMALE; MALE; MEDICAL SOCIETY; TREATMENT OUTCOME;

CONSENSUS; FEMALE; HEALTH STATUS; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 85027410213     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-161055     Document Type: Article

References (58)

1. Lees AJ, Hardy J, & amp; Revesz T (2009) Parkinson's disease. Lancet, 373, 2055-2066.
2. Kowal SL, Dall TM, Chakrabarti R, Storm MV, & amp; Jain A (2013) The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord, 28, 311-318.
3. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen H-C, Stovner LJ, Vallat J-M, Van den Bergh P, den Bergh PV, van Os J, Vos P, Xu W, Wittchen H-U, Jönsson B, & amp; Olesen J (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol, 21, 718-779.
4. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, & TannerCM(2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68, 384-386.
5. Porter ME (2010) What is value in health care? N Engl J Med, 2477-2481.
6. Cheng EM, Siderowf A, Swarztrauber K, Eisa M, Lee M, & amp; Vickrey BG (2004) Development of quality of care indicators for Parkinson's disease. Mov Disord, 19, 136-150.
7. Cheng EM, Tonn S, Swain-Eng R, Factor SA, Weiner WJ, & amp; Bever CT (2010) Quality improvement in neurology: AAN Parkinson disease quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology, 75, 2021-2027.
8. Nijkrake MJ, Keus SHJ, Ewalds H, Overeem S, Braspenning JCC, Oostendorp RAB, Hendriks EJM, Bloem BR, & amp; Munneke M (2009) Quality indicators for physiotherapy in Parkinson's disease. Eur J Phys Rehabil Med, 45, 239-245.
9. National Parkinson Foundation (2012) Parkinson's Outcomes Project: Report to the Community.
10. Our Standard Sets | ICHOM-International Consortium for Health Outcomes Measurement.
11. Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, & amp; Huland H (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol, 67, 460-467.
12. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, Ruessmann A, Odin P, Macphee G, Stocchi F, Ondo W, Sethi K, Schapira AHV, Martinez Castrillo JC, & Martinez-Martin P (2010) The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Mov Disord, 25, 704-709.
13. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, & amp; Chaudhuri KR (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord, 26, 399-406.
14. Müller B, Assmus J, Herlofson K, Larsen JP, & amp; Tysnes O-B (2013) Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord, 19, 1027-1032.
15. Chaudhuri KR, Odin P, Antonini A, & amp; Martinez-Martin P (2011) Parkinson's disease: The non-motor issues. Parkinsonism Relat Disord, 17, 717-723.
16. van der Eijk M, Faber MJ, Al Shamma S, Munneke M, & amp; Bloem BR (2011) Moving towards patient-centered healthcare for patients with Parkinson's disease. Parkinsonism Relat Disord, 17, 360-364.
17. Visser M, Marinus J, Stiggelbout AM, & amp; Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA-AUT. Mov Disord, 19, 1306-1312.
18. Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A,Williams AJ, & amp; Olanow CW(2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Mov Disord, 21, 916-923.
19. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, OndoW, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, & amp; Schapira AHV (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord, 22, 1901-1911.
20. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, & LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord, 23, 2129-2170.
21. Schrag A, Barone P, Brown RG, Leentjens AFG, Mcdonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, & amp; Goetz CG (2007) Depression rating scales in Parkinson's disease: Critique and recommendations. Mov Disord, 22, 1077-1092.
22. Williams JR, Hirsch ES, Anderson K, Bush AL, Goldstein SR, Grill S, Lehmann S, Little JT, Margolis RL, Palanci J, Pontone G, Weiss H, Rabins P, & amp; Marsh L (2012) A comparison of nine scales to detect depression in Parkinson disease: Which scale to use?. Neurology, 78, 998-1006.
23. Leentjens AFG, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE,Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, & amp; Goetz CG (2008) Anxiety rating scales in Parkinson's disease: Critique and recommendations. Mov Disord, 23, 2015-2025.
24. Leentjens AFG, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, & amp; Goetz CG (2008) Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations. Mov Disord, 23, 2004-2014.
25. FernandezHH,Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, PoeweW, Rascol O, Sampaio C, Stebbins GT, & amp; Goetz CG (2008) Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord, 23, 484-500.
26. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, & SchragA(2010) Fatigue rating scales critique and recommendations by the Movement Disorders Society Task Force on rating scales for Parkinson's disease. Mov Disord, 25, 805-822.
27. Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, & amp; Goetz CG (2010) Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. Mov Disord, 25, 2704-2716.
28. Watson GS, Cholerton BA, Gross RG, Weintraub D, Zabetian CP, Trojanowski JQ, Montine TJ, Siderowf A, & amp; Leverenz JB (2013) Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania. Alzheimers. Dement, 9, 609-614.
29. Kulisevsky J, & amp; Pagonabarraga J (2009) Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment. Mov Disord, 24, 1103-1110.
30. Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti K, Yang C, Poewe W, Rascol O, Sampaio C, Stebbins GT, & amp; Goetz CG (2009) Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation-critique and recommendations by Movement Disorders Task Force on Rating Scales for Parkinson's Disease. 24 635-646.
31. Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, & amp; Goetz CG (2013) Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol, 260, 228-236.
32. Gallagher DA, Goetz CG, Stebbins G, Lees AJ, & Schrag A (2012) Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord, 27, 79-83.
33. Beck AT, Steer RA, & amp; Carbin MG (1988) Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev, 8, 77-100.
34. Spielberger CD, Gorsuch RL, & amp; Lushene R (1983) Manual for the state-trait anxiety inventory. Consulting Psychologists' Press.
35. Koski L, Xie H, & amp; Finch L (2009) Measuring cognition in a geriatric outpatient clinic: Rasch analysis of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol, 22, 151-160.
36. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, & amp; Seidl L (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov Disord, 19, 1020-1028.
37. Hoehn MM, & amp; Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology, 17, 427-442.
38. McRae C, Diem G, Vo A, O'Brien C, & amp; Seeberger L (2002) Reliability of measurements of patient health status: A comparison of physician, patient, and caregiver ratings. Parkinsonism Relat Disord, 8, 187-192.
39. Martinez-Martin P, Jeukens-Visser M, Lyons KE, Sampaio C, Stebbins GT, Goetz CG, & amp; Schrag A (2011) Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations. Mov Disord, 26, 2371-2380.
40. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, & amp; Hyman N(1997) The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age Ageing, 26, 353-357.
41. Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, & amp; Goetz CG (2011) Wearing-off scales in Parkinson's disease: Critique and recommendations. Mov Disord, 26, 2169-2175.
42. Qutubuddin AA, Pegg PO, Cifu DX, Brown R, McNamee S, & amp; CarneW(2005) Validating the Berg Balance Scale for patients with Parkinson's disease: A key to rehabilitation evaluation. Arch Phys Med Rehabil, 86, 789-792.
43. Schlenstedt C, Brombacher S, Hartwigsen G, Weisser B, Möller B, & amp; Deuschl G (2015) Comparing the Fullerton Advanced Balance Scale with the Mini-BESTest and Berg Balance Scale to assess postural control in patients with Parkinson disease. Arch Phys Med Rehabil, 96, 218-225.
44. Foreman KB, Addison O, Kim HS, & amp; Dibble LE (2011) Testing balance and fall risk in persons with Parkinson disease, an argument for ecologically valid testing. Parkinsonism Relat Disord, 17, 166-171.
45. Morris S, Morris ME, & amp; Lansek R (2001) Reliability of measurements obtained with the Timed Up & amp; Go test in people with Parkinson disease. Phys Ther, 81, 810-818.
46. Jenkinson C, Fitzpatrick R, PetoV, Greenhall R, & HymanN (1997) The PDQ-8: Development and validation of a shortform Parkinson's disease questionnaire. Psychol Health, 12, 805-814.
47. Peto V, Jenkinson C, & amp; Fitzpatrick R (1998) PDQ-39: A review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 245(Suppl 1), S10-S14.
48. Tan LCS, Luo N, Nazri M, Li SC, & amp; Thumboo J (2004) Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson's disease patients in Singapore. Parkinsonism Relat Disord, 10, 493-499.
49. Poletti M, Emre M, & amp; Bonuccelli U (2011) Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord, 17, 579-586.
50. Bennett DA, Arnold SE, Valenzuela MJ, Brayne C, & amp; Schneider JA (2014) Cognitive and social lifestyle: Links with neuropathology and cognition in late life. Acta Neuropathol, 127, 137-150.
51. Guo X, Song W, Chen K, Chen X, Zheng Z, Cao B, Huang R, Zhao B, Wu Y, & amp; Shang H-F (2013) Gender and onset age-related features of non-motor symptoms of patients with Parkinson's disease-a study from Southwest China. Parkinsonism Relat Disord, 19, 961-965.
52. Lipnicki DM, Sachdev PS, Crawford J, Reppermund S, Kochan NA, Trollor JN, Draper B, Slavin MJ, Kang K, Lux O, Mather KA, & amp; Brodaty H (2013) Risk factors for latelife cognitive decline and variation with age and sex in the Sydney Memory and Ageing Study. PLoS One, 8, e65841.
53. Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y, Oertel W, Ju Y-E, Puligheddu M, Jennum P, Pelletier A, Wolfson C, Leu-Semenescu S, Frauscher B, Miyamoto M, Cochen De Cock V, Unger MM, Stiasny-Kolster K, Fantini ML, & amp; Montplaisir JY (2012) A single-question screen for rapid eyemovement sleep behavior disorder:Amulticenter validation study.Mov Disord, 27, 913-916.
54. European Social Survey (2012) APPENDIX A4 The measurement of legal marital and relationship status in the ESS.
55. UNESCO (2011) International Standard Classification of Education (ISCED) 2011, UNESCO Institute for Statistics.
56. (2012) Patient Reported Outcome Measures (PROMs) in England: The case-mix adjustment methodology, Department of Health, prepared by the PROMs team, Policy, Strategy and Finance Directorate.
57. Crizzle AM, Classen S, & amp; Uc EY (2012) Parkinson disease and driving: An evidence-based review. Neurology, 79, 2067-2074.
58. Tennant A, Penta M, Tesio L, Grimby G, Thonnard J-L, Slade A, Lawton G, Simone A, Carter J, Lundgren-Nilsson A, Tripolski M, Ring H, Biering-Sørensen F, Marincek C, Burger H, & amp; Phillips S (2004) Assessing and adjusting for cross-cultural validity of impairment and activity limitation scales through differential item functioning within the framework of the Rasch model: The PRO-ESOR project. Med Care, 42, I37-I48.